PALVELLA THERAPEUTICS, INC.
About PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases and vascular malformations for which there are no FDA-approved therapies. The company is founded and led by rare disease drug development veterans and is advancing a pipeline based on its patented QTORIN™ platform. It completed a merger with Pieris Pharmaceuticals and began trading on Nasdaq under the ticker PVLA. The company is headquartered in Wayne, PA.
- 🔗 Palvella Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Palvella Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - Fri, 12/13/2024 - 14:55
- 🔗 Palvella Therapeutics Announces Pricing of Upsized Public Offering
- 🔗 Institutional investors in Palvella Therapeutics, Inc. (NASDAQ:PVLA) have had a wonderful week after share price increased 13%
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Completed merger with Pieris Pharmaceuticals leading to Nasdaq listing under PVLA.
- Raised $78.9M in concurrent private placement upon going public.
- Pipeline focused on QTORIN platform for rare genetic skin diseases.
- CEO Wesley Kaupinen holds 15% of shares with significant insider ownership.
Ask StreetZero about PALVELLA THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (Nasdaq) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account